RxDoctor Payments Data

Christina Zinna

Psychiatric/Mental Health · Lawrence, MANPI 1720363534

Payments from drug & device makers

$1,447in general payments, 2019–2025

Across 74 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$852
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$171
  • Sunovion Pharmaceuticals Inc.$161
  • Lundbeck LLC$71
  • E.r. Squibb & Sons, L.L.C.$64
  • Johnson & Johnson$59
  • plus $68 from 2 others

What the payments were for

  • Food & beverage$1,38696%
  • Education$614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,447 in reported general payments places this provider in the 80th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,335
Medicare patients
90
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine66$432,102
IngrezzaValbenazine Tosylate37$291,515
VraylarCariprazine Hcl112$184,205
Invega SustennaPaliperidone Palmitate30$102,544
RexultiBrexpiprazole26$62,433
TrintellixVortioxetine Hydrobromide47$32,412
LatudaLurasidone Hcl13$25,120
VyvanseLisdexamfetamine Dimesylate44$17,572
Aripiprazole83$13,527
LexaproEscitalopram Oxalate16$11,702
Paliperidone ErPaliperidone19$5,783
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine63$3,541
Buspirone Hcl153$3,508
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine145$3,408
Lurasidone Hcl61$3,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$852$195,907128 claims
Johnson & JohnsonInvega Sustenna$59$102,54430 claims
Otsuka America Pharmaceutical, Inc.Rexulti$43$62,43326 claims
Sunovion Pharmaceuticals Inc.Latuda$161$25,12013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →